As the European Union takes bold strides towards harmonizing and enhancing its healthcare landscape, the imminent implementation of the Joint Clinical Assessment (JCA) stands as a pivotal moment. With less than 1 year remaining until its full integration, we invite you to explore a wealth of insights that delve deep into the intricacies of this transformative initiative.
Unveiling the path forward, our experts offer unparalleled insights into the current status of JCA and shed light on the uncertainties that lie ahead, and the solutions to help you navigate those.
One expert partner, from global strategy to local implementation
Achieve local reimbursement globally
Maximize product value
Navigate Health Technology Assessments (HTAs)
Insight
Panel discussion: The EU JCA process
Seeking to substitute multiple country-specific clinical assessments and establish a more streamlined, transparent and less bureaucratic single market for health technologies, the EU JCA will pose both a threat and an opportunity for getting innovative medicines to patients in Europe.
Watch our panel discussion with EFPIA, MSD, PharmaLex and Vintura to explore the ins and outs of the JCA and the next steps to best prepare.
Insight
Q&A – Preparing for the EU Joint Clinical Assessment (JCA) process
During a panel discussion on the European Joint Clinical Assessment (JCA) process, led by Tommy Bramley, Senior Vice President, Global Consulting and Market Access, Cencora, market access and healthcare system experts offered their perspectives on the challenges and opportunities pharmaceutical and biotechnology companies are likely to encounter. In this article, panelists delve into the questions received from the audience.
Insight
